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Abstract
Background: Epstein-Barr virus has been proved to be associated with many of the human
malignancy including gastric carcinoma, one of the most important human malignancies in the
world. There has been no study about the presence of EBV in gastric adenocarcinoma in Iran.
Methods: We examined the presence of EBV in 273 formalin fixed paraffin-embedded cases of
gastric carcinoma from Cancer institute of Tehran University, from 1969 to 2004. In situ
hybridization of EBV-encoded small RNA-1 (EBER-1) was conducted. The strain of positive cases
was examined by means of polymerase chain reaction and/or restriction fragment length
polymorphism analysis.
Results: We found 9 (3%; 95% CI = 1–5%) EBV positive cases. The gender difference was not
statisticaly significant. The proportion of EBV-GC cases in diffuse type was higher than intestinal
type (OR = 0.08; 95% CI = 0.002–0.64). EBV-GC cases had no relation with age, location and
invasion. Six out of 9 EBV-GC cases were born during the period between 1928 and 1930. All 9
cases were Type A. Prototype F was seen in 6 out of 8 cases. Type "i" was found in 8 cases and
type I in 1 case. XhoI+ and XhoI- polymorphism accounted 6 and 3 of the cases, respectively.
Conclusion: Our study is the first to describe the frequency of EBV-GC in Iran and the Middle
East, highlighting a very low prevalence with specific clinicopathologic features. The predominance
of EBV-GC birth year in a fixed period, suggests that EBV infection or other events at early
childhood may be related to the development of EBV-GC later in the life. The predominance of the
type "i" and XhoI+ cases are contradictory to other studies in Asia and is similar to what is reported
from Latin American countries.
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Background
Epstein-Barr virus (EBV) is a ubiquitous double stranded
DNA virus from human herpes virus family, which has B-
lymphotropism [1]. More than 90% of adults in the world
have serologic evidence of infection with this virus [1]. It
is acquired during early childhood and the age of infec-
tion is much lower in undeveloped countries with low
socioeconomic condition [1]. Following primary infec-
tion, the virus establishes a life-long latent infection in the
B-cell lymphocytes where it is present in 1 in 105–106 cir-
culating cells [2]. It expresses some antigens in this latent
phase, which are proved to have some oncogenic proper-
ties [3-8]. There are many documents about causal associ-
ation between EBV and lymphoid malignancies such as
Burkitt's lymphoma in equatorial Africa [9], nasal T/NK
cell lymphoma [10], Hodgkin's lymphoma [11] and B-
cell lymphoma in immunosuppressed patients [12]. EBV
has also the capacity of infecting epithelial cells, and also
has tumorogenic effect in these cells from which the
nasopharyngeal carcinoma is one of the important proto-
types [13].
The first report of EBV involvement in gastric carcinoma
was published in 1990 in lymphoepithelial carcinoma of
the stomach [14]. Consequently, in 1992 Shibata and
Weiss reported EBV detection in 16% of ordinary gastric
carcinoma in U.S. [15]. Since then, the prevalence of EBV-
associated gastric carcinoma (EBV-GC) has been investi-
gated and reported in various countries which ranged
between 3 to 18% [15-34] with the lowest prevalence in
Papua New Guinea, Pakistan and Korea which is between
1 to 3% and the highest in Germany and U.S. which is 16
to 18%.
There are many evidences of causal relationship between
EBV and gastric carcinoma such as: monoclonality of the
viruses in neoplastic cells which was demonstrated by
unique terminal repeat of EBV DNA [35]; uniform pres-
ence of EBV in all tumoral cells detected by in situ hybrid-
ization of EBER-1, but not in surrounding epithelial cells
[15-34] and elevation of IgG and IgA antibodies against
viral capsid antigen several months before clinical presen-
tation of the disease [36].
EBV-GC shows some constant characteristic clinicopatho-
logic features such as predisposition to upper two-third of
the stomach [15-17,19-31]; a moderately differentiated
tubular to poorly differentiated solid type of histology
[16-22,32,33]; having no effect in stromal invasion and
survival [15,16]; and male predominance in most of the
studies. However, the last one is not seen in some excep-
tional studies which are performed in Mexico [32,37],
Chile [16] and China [38]. Age dependence is not evident
in most studies. However studies in Colombia [19], and
Kazakhstan [28] show a higher prevalence among
younger patients.
EBV has two major types, type 1 and type 2 that differ in
their capacity to transform B-lymphocytes into a state of
continuous proliferation [39]. Type 1 is predominant in
Western and Asian countries while B type is predominant
in Africa and is seen more commonly in immunosup-
pressed patients [40,41]. Besides, there are three other var-
iants, which are distinguished by restriction fragment
length polymorphism (RFLP) using BamHI and XhoI
restriction endonuclease enzymes. At the BamHI-F region
Prototype F has the worldwide distribution and 'f' variant
which has an extra site for enzyme is predominant in
southern China and is associated with nasopharyngeal
carcinoma [42,43]. Polymorphism in BamHI-W1/I1
boundary region leads to two variants; type I and 'i'. Type
I which is predominant in Japan and China has no site for
BamHI enzyme [44,45] and type 'i' with an extra BamHI
site is seen more commonly in Western countries [46].
Finally, polymorphism in XhoI restriction site in axon 1 of
the LMP1 gene defines XhoI+ which is more prevalent in
Western countries [47] and XhoI-, which is frequently
seen in Asia [44].
Iran is one of the countries which have a high incidence of
gastric carcinoma with an annual incidence of 26.1 per
100,000 for males and 11.1 for females. It is the second
most prevalent cancer and the first leading cause of can-
cer-related deaths in men in Iran [48]. However, there is
no study about the prevalence or genotype of EBV in gas-
tric cancer in this area. Therefore, we decided to evaluate
it in the oldest referral center for gastric cancer in Iran.
Methods
Specimens
We examined 273 surgically resected gastric cancer cases
in this study. The cases were randomly selected from 1325
gastric cancer cases registered in cancer institutes of
Tehran University between 1969 – 2004 which have intact
paraffin blocks and pathologic reports. Formalin fixed
paraffin-embedded tissue from these cases were selected
and sent to Kagoshima University Graduate School of
Medical and Dental Sciences, Japan, for further molecular
evaluations. Pathologic data were obtained with re-evalu-
ation of H&E stained slides by two pathologists (AA &
SGS). All available demographic data were obtained from
the available pathologic and medical reports of the
patients.
Pathology
All the specimens were re-classified in regard of predomi-
nant histological pattern as intestinal and diffuse type
according to Lauren classification [49] and sub-classified
according to the guidelines of the Japanese research soci-Diagnostic Pathology 2007, 2:25 http://www.diagnosticpathology.org/content/2/1/25
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ety for gastric cancer [50] to well differentiated tubular
adenocarcinoma (tub1), moderately differentiated aden-
ocarcinoma (tub2), solid poorly differentiated adenocar-
cinoma (por1), non-solid poorly differentiated
adenocarcinoma (por2), signet ring cell carcinoma (sig),
mucinous carcinoma (muc) and poorly differentiated
lymphoepithelial-like carcinoma (LE).
The tumors location according to predominant location
of the lesions were classified as upper third or cardia, mid-
dle third or body and lower third or antrum according to
the guidelines of the Japanese research society for gastric
cancer [50]. There was no multifocal case in our study.
The depth of invasion was classified as mucosal, sub-
mucosal, muscularis propria and serosal involvement.
In situ hybridization
EBV was identified by the expression of EBV-encoded
small RNA-1 (EBER-1). In situ hybridization with a com-
plementary digoxigenin-labeled 30-base oligomer was
used to detect the EBER-1 according to the procedure pre-
viously described by Chang et al [51]. 4–5-µm sections
mounted on silane-coated glass slides were prepared for
each case. The tissue on the slides was deparaffinized,
rehydrated, predigested with pronase, prehybridized, and
then hybridized overnight at 37°C with 0.5 ng digoxi-
genin-labeled probe. The hybridization signal was
detected by an antidigoxigenin antibody-alkaline phos-
phatase conjugate. Sections from a patient with known
EBER-positive gastric carcinoma were used for a positive
control, and sense probe to EBER-1 was used for a nega-
tive control for each procedure.
Preparation of DNA
The formalin-fixed and paraffin-embedded specimen was
cut into 10 µm thick slices, and DNA sample was prepared
following the method described by Greer et al [52].
Briefly, the slices were treated with xylene and ethanol and
centrifuged at 22,000 g for 20 min, and the resulting pellet
was resuspended in 100 µl of digestion buffer (1 M Tris,
pH 8.0, 50 mM EDTA, 0.5% Tween 20) with 200 µg/ml
Proteinase K and incubated at 55°C overnight. After 10
min boiling at 100°C, extraction and precipitation of
DNA was carried out with phenol-chloroform and etha-
nol, respectively.
Primers and probes
Four different regions, EBNA-3C, BamHI-F, BamHI-W1/
I1, and XhoI site in LMP1, were used to determine viral
genotypes. Table 1 shows the list of primer sets and probes
used in the present study.
Types 1 and 2 were recognized by amplification of U2
region of EBNA-3C gene by primers described by Sample
et al [53] which yielded 153 and 246-bp fragments,
respectively. They are recognized by Southern blot hybrid-
ization (SBH) with type-specific internal probes described
by Sample et al [53]. The BamHI-F region was amplified
by the primers set described by Lung et al [54]. The conse-
quent 198-bp fragment was digested by BamHI restriction
enzyme which yelled a 198-bp fragment in the case of
Table 1: List of primers and probes used in this study
Genotype Sequence Type by probe or size after RE1 digestion Reference
EBNA-3C
Primers
Sense 5'-AGAAGGGGAGCGTGTGTTGT-3'
Antisense 5'-GGCTCGTTTTTGACGTCGGC-3 Sample et al. (53)
Probes
Type 1 5'-GAAGATTCATCGTCAGTGTC-3' 153 bp2
Type 2 5'-CCGTGATTTCTACCGGGAGT-3' 246 bp
BamHI-F
Primers
Sense 5'-TCCCACCTGTTACCACATTC-3' Prototype F: 198 bp Lung et al. (54)
Antisense 5'-GGCAATGGGACGTCTTGTAA-3' Variant "f": 127 + 71 bp
Probe 5'-AAGGCTACCGTGCTAATTACCTCC-3' Hudson et al. (55)
BamHI-W1/I1
Primers
Sense 5'-ACCTGCTACTCTTCGGAAAC-3' Type I: 205 bp Lung et al. (54)
Antisense 5'-TCTGTCACAACCTCACTGTC-3' Type "i": 130+75 bp
XhoI site in LMP1
Primers
Sense 5'-AACAGTAGCGCCAAGAGGAG-3' XhoI+:113 bp Sandvej et al. (56)
Antisense 5'-ATGGAACACGACCTTGAGAGG-3' XhoI-: 67+46 bp
1Restriction enzyme; 2Base pairsDiagnostic Pathology 2007, 2:25 http://www.diagnosticpathology.org/content/2/1/25
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wild type F and 127-bp and 71-bp fragments in the case of
'f' variant. The wild-type F and the f variants were con-
firmed by SBH with the internal probe as described before
[55]. To distinguish I/i variants, the BamHI-W1/I1 region
was amplified using the primer set described by Lung et al
[54]. Digestion with BamHI restriction enzyme yelled
205-bp fragment in type I and 130-bp and 75-bp frag-
ments in the case of 'i'. They were also confirmed by SBH
with a cloned BamHI-I DNA fragment probe. Analysis of
polymorphism in exon 1 of LMP1 gene was performed
using a primer set described by Sandvej et al [56] which
resulted 113-bp fragments. After digestion with XhoI
restriction enzyme, XhoI+ cases which contain XhoI cleav-
age site (XhoI kept) show 67-bp and 46-bp fragments but
XhoI- cases show the original undigested 113-bp PCR
product. The 113 bp fragment of PCR product of B95-8
cell line was used as the probe to confirm XhoI cleavage
site of LMP1 by SBH [57].
For type 1, wild type F, type I, and XhoI- viruses the B95-8
cell line was used as positive control. The cell lines AG786
and Akata and the cloned BamHI-'f' and BamHI-"i" DNA
fragments served as positive controls for type 2, XhoI-, "f"
variant, and type "i" viruses, respectively. Human herpes
virus 6 infected cell line MOLT-4 used as negative control
[58].
Polymerase chain reaction
Amplification of target DNAs was carried out using 2 µl of
DNA and mixture of 10 mM Tris-HCl, pH 8.0, 50 mm
KCl, 1.5 mM MgCl2, 200 µM dNTPs, 1 µM of each primer
and 1.0 U Taq Polymerase (Hot Star, Qiagen, Germany)
in a final volume of 25 µl mixture. The protocol used for
amplification of EBNA-3C gene was one cycle at 95°C for
15 min, followed by 40 cycles of denaturation at 95°C for
1 min, annealing at 46°C for 1 min and elongation at
72°C for 1 min and finally ended with 5 min at 72°C. The
protocol used for BamHI-F, BamHI-W1/I1 and XhoI site
amplification was one cycle at 95°C for 5 min followed by
40 cycles of denaturation at 95°C for 1 min, annealing at
43°C for 1 min and elongation at 72°C for 1 min and
finally ended with 5 min at 72°C. Electrophoresis in a 2%
agarose gel and staining with 0.5 µg/ml of ethidium bro-
mide was carried out to identifying the PCR products.
Restriction fragment length polymorphism analysis
Amplified DNA products (15 µl) were digested with 10 U
of BamHI or XhoI restriction enzymes, according to man-
ufacturer's instruction and visualized by electrophoresis
in a 2% agarose gel stained with 0.5 µg/ml of ethidium
bromide and transferred onto a nylon membrane for SBH.
Southern blot hybridization
Specificity of PCR reaction was confirmed by SBH. The
electrophoretic DNA was transferred onto a Hybond N+
nylon membrane (Amersham, Pharmacia Biotech, UK) by
capillary blotting using 0.4 N NaOH solution. Mem-
branes were prehybridized with hybridization buffer for 1
h at 42°C. After adding the probe, hybridization was car-
ried out overnight at 42°C. Probes of types A and B, and
BamH-I F were labeled with Dig oligonucleotide 3'-end
labeling kit and detected by Dig luminescent detection kit
(Boehringer Mannheim, Germany). For detecting the
BamHI-I fragment and XhoI polymorphism in LMP1,
hybridization was carried out using the ECL direct labe-
ling and detection kit (Amersham, Pharmacia Biotech,
UK) according to the manufacturer's instructions.
Statistical analysis
Statistical analysis was done using LogExact 7.0 software
(a statistical package for regression procedure featuring
exact method); Cytel Studio 7.0.0 package (Cytel Software
Corporation, 2005). Exact test of binary logistic analysis
was conducted to compare the proportion of EBV positive
cases among gastric adenocarcinoma. Sex, age groups
(<50, 50–69 and ≥ 70 years), anatomical location of
tumor (antrum, body and cardia), invasion of tumor
(serosa, others) and Lauren's histological classification
were included as independent variables. Multinominal
variables were divided to n-1 dummy binominal variables
(n was the number of categories). Odds ratio with 95%
confidence interval was calculated for each category. Type
1 error (α) was set at 0.05. All p values were two-sided.
Results
We examined 273 gastric cancers including 196 (72%)
males and 77 (28%) females. The mean age was 57.3 ±
11.3 (SD) years (range: 24–90; median: 58). Most of them
(108 cases; 66%) were between 50 to 69 years, 54 (20%)
cases were under 50 and the remaining were over 70 years.
One hundred thirty cases (48%) were located in antrum,
and 64 (23%) and 71 (26%) cases were located in body
and cardia, respectively. In 5 cases the location was not
defined and in 3 cases all the gastric wall were involved
(linitis plastica) which were not included in statistical
analysis. As shown in table 2, most of the cases were intes-
tinal type (56%).
Prevalence of EBV positive cases
EBER-1 was detected in nine out of 273 cases (3%) which
were considered as EBV-GC. The signal was restricted only
to the nuclei of tumoral cells but not found in non-
tumoral cells (Fig. 1).
Factors associated with EBV positive cases
Table 3 shows the frequencies of EBV-GC by age, gender,
location, histology and invasion as well as the result of
logistic analysis.Diagnostic Pathology 2007, 2:25 http://www.diagnosticpathology.org/content/2/1/25
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Gender and age
Eight out of 188 (4%) male cases and 1 out of 76 (1%)
female cases were EBV positive. Although there was a male
predominance in this study, it was not statistically signifi-
cant (p = 0.5). There was also no relationship between age
and EBV-GC (p = 1).
Tumor location
According to anatomic location, 5 out of 64 (8%) body
tumors, 1 out of 71 (1%) cardiac tumors and 3 out of 130
(2%) antral tumors were EBV associated. Although most
of EBV-GC were located in upper two-thirds, it was not
significant statistically (p = 0.1).
Histological type
Based on Lauren's classification, 8 out of 121 (7%) diffuse
type cases were EBV associated but only 1 out of 152 intes-
tinal type was EBV positive, which was statistically signif-
icant (p  = 0.009). According to Japanese classification,
por2 and por1 were the predominant histologic types in
EBV-GC (Table 2), but regarding the low number of cases
in each group statistical analysis could not be performed.
Invasion
In this study there were only 2 cases which were limited to
submucosa and none of them shows EBER-1 signal in
ISH. Thus, considering of the low number, these cases
were not considered in statistical analysis. There was no
difference between EBV positive and negative cases
regarding invasion to serosa and muscularis propria (p =
0.24).
Other findings
The noteworthy point in our study was the fact that 6 out
of 9 EBV-GCs patients were born between "1928–1930".
However, the statistical analysis was not made because of
the low number.
Genotyping
The subtype of EBV genome was determined in all 9 cases.
All of our cases were type 1. The BamHI-F region was
amplified successfully in 8 out of 9 of EBV-GCs, which six
of them showed prototype F (Fig. 2). Amplification of
BamHI-I/WI1 was successful in all of the cases and, except
one; all the cases were "i" type (Fig. 3). Analysis of poly-
morphism in exon 1 of LMP1 gene revealed that 3 cases
were XhoI- and 6 cases were XhoI+ (Fig 4). Table 4 summa-
Table 3: Result of logistic analysis
Variables EBER+/N1 (%) OR2 95% CI2
Gender
Female 1/76 (1) 1 reference
Male 8/188 (4) 0.3 0.01–2.96
P = 0.595
Age
≥ 70 1/36 (3) 1 reference
50–69 5/180 (3) 0.8 0.08–44.62
<50 3/54 (6) 1.3 0.08–81.25
P for trend = 1.0
Location
Upper 1/71 (1) 1 reference
Middle 5/64 (8) 6.0 0.1–77.86
Lower 3/130 (2) 1.4 0.63–296.7
P for heterogeneity = 1.64
Histology
Diffuse 8/121 (7) 1 reference
Intestinal 1/152 (1) 0.08 0.002–0.64
P = 0.009
Invasion
Muscle 3/33 (9) 1 reference
serose 6/222 (3) 3.6 0.47–24.03
P = 0.243
1Total number in each group; 2OR and 95% confidence interval were 
obtained from exact test of binary logistic analysis.
Table 2: Distribution of EBER-1 positive gastric carcinomas by 
histological type and gender
Histology1 Male Female Total
EBER+/N2 (%) EBER+/N (%) EBER+/N (%)
Intestinal 1/113 (1) 0/39 (0) 1/152 (1)
pap 0/11 (0) 0/3 (0) 0/14 (0)
tub1 0/36 (0) 0/11 (0) 0/47 (0)
tub2 1/50 (2) 0/16 (0) 1/66 (1)
muc 0/16 (0) 0/9 (0) 0/25 (0)
Diffuse 7/83 (8) 1/38 (3) 8/121 (7)
por1 3/34 (8) 1/16 (6) 4/50 (8)
por2 4/40 (10) 0/18 (0) 4/58 (8)
sig 0/9 (0) 0/4 (0) 0/13 (0)
1 pap:papillary adenocarcinoma; tub1:well differentiated tubular 
adenocarcinoma; tub2:moderately differentiated adenocarcinoma; 
por1:solid poorly differentiated adenocarcinoma; por2:non-solid 
poorly differentiated adenocarcinoma; sig: signet ring cell carcinoma; 
muc:mucinous carcinoma; 2 total number of cases in each group 
(Based on Japanese research society for gastric cancer)
A case of EBV positive gasrtric carcinoma Figure 1
A case of EBV positive gasrtric carcinoma. Moderately 
differentiated tubular adenocarcinoma with occasional tubul 
formation (A); nuclear EBER positive signal in all tumoral cells 
detected with in situ hybridization (B).Diagnostic Pathology 2007, 2:25 http://www.diagnosticpathology.org/content/2/1/25
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rized all the demographic, pathologic and genotypic data
of the EBV-GC in this study.
Discussion
The present study detected EBV-GCs in 3% of gastric car-
cinomas and suggested that the majority of gastric carci-
nomas in Iran are EBV-negative. There were no LELCs,
which are well known to be strongly associated with EBV
[59]. Lace pattern, which is a unique morphology in EBV-
positive early gastric carcinoma [60], was not seen in our
study. This frequency is among the lowest frequencies in
the world. As mentioned above, according to WHO classi-
fication, the north of Iran is considered as one the regions
with high gastric carcinoma frequency in the world [61].
The sparse studies in Iran also show this fact except that
they show more or less homogeneity throughout the
country [48,62,63]. Thus, the low EBV-GC frequency in
Iran supports the previous hypothesis that high risk coun-
tries for GC have low rates of EBV-GC [64]. This also con-
firms the belief that it is low in Asia as the prevalence of
3% in Korea [25], 6% in Japan [24], 6% in china [26], 5%
in India [18], 2% in Pakistan [29] and maximal 10% in
Malaysia [27], Taiwan [21] and Kazakhstan [28]. How-
ever, this is much lower than Kazakhstan frequency, (our
nearby country) with many similarities in the custom and
socioeconomic conditions.
The prevalence of EBV-GC in diffuse type gastric carci-
noma was more in our study, a fact which was seen in
most of studies of Latin America [16,32] and some coun-
tries in Asia such as Korea [25], China [26] and India [18].
However, there are many contradictory studies which did
not show any relationship in this concept
[15,17,19,23,33]. Koriyama et al [23] in their classic study
proposed that there are many other factors which have
effect on the incidence of diffuse type gastric cancer such
as age, gender and location and the conflicting results in
different studies could be explained by the difference in
distribution of these factors.
Although the ratio of male/female was approximately 4 in
our study, it was not significant in statistical analysis. The
absence of gender preference was seen in other studies in
Mexico [32,37] Chile [16] and one area in China [38].
Result of southern blot hybridization for BamHI-W1/I1  region Figure 3
Result of southern blot hybridization for BamHI-W1/
I1 region. Each sample was loaded in 2 lanes with and with-
out enzyme, respectively from left. In sample one there is no 
band in the second lane which suggests that the PCR product 
was digested but we could not detect the fragmented bands 
since the original band contained small number of DNA cop-
ies, so we regarded it as type "i". Samples 2, 5, and 6 are 
cleaved which means they are type "i". Polymorphism of sam-
ples 3 and 4 were not determined in this experiment. (+: 
positive control; +/enz: positive control with enzyme; -: nega-
tive control).
Table 4: Clinico-pathologic and genetic characteristics of EBV-GC
Birth 
year
Diagnostic 
year
Age Gender Lacation Invasion Histology 
Lauren/WHO
EBNA-3 
type A/B
BamHI-F type F/"f" BamHI-I type I/"i" XhoI +/-
1 1949 1981 32 Male Lower Muscle Diffuse/por1 A F "i" +
2 1929 1982 53 Male Middle Muscle Diffuse/por1 A F "i" -
3 1928 1983 55 Male Middle Serosa Intestinal/tub2 A F "i" +
4 1928 1983 55 Male Middle Serosa Diffuse/por2 A F I +
5 1940 1983 43 Female Lower Muscle Diffuse/por1 A F "i" -
6 1930 1986 56 Male Middle Serosa Diffuse/por2 A ND1 "i" +
7 1928 1988 60 Male Upper Serosa Diffuse/por1 A F "i" +
8 1928 2001 73 Male Middle Serosa Difuse/por2 A "f' "i" -
9 1953 2002 49 Male Lower Seroasa Diffuse/por2 A "f" "i" +
1Not determined; tub2: moderately differentiated adenocarcinoma por1: solid poorly differentiated adenocarcinoma; por2: non-solid poorly 
differentiated adenocarcinoma
Result of southern blot hybridization for BamHI-F region Figure 2
Result of southern blot hybridization for BamHI-F 
region. Four specimens are seen in this figure, each sample 
was loaded in 2 lanes with and without enzyme, respectively 
from left. The first specimen was not amplified in this experi-
ment. The other three specimens were not cleaved by Bam-
HI enzyme which means they are wild-type F. (+: positive 
control; +/enz: positive control with enzyme; -: negative con-
trol).Diagnostic Pathology 2007, 2:25 http://www.diagnosticpathology.org/content/2/1/25
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However, we should consider that the low number of pos-
itive cases in our study might be the reason of insignifi-
cant result in the analysis. Meanwhile, Koriyama et al [23]
show that the gender preference for EBV is restricted to dif-
fuse type GC and is not seen in intestinal type. Neverthe-
less, regarding the low number of our cases, we could not
perform the analysis separately for each type.
Increase in cancer of upper portion of the stomach despite
decrease in total incidence of gastric cancers is seen in
many studies around the world [65,66]. There are also
many evidences that this type of gastric cancer has differ-
ent risk factors [67-69]. EBV is one of them [15-31].
Abdirad et al [70] also show that there is such increase in
cancer of upper third of stomach in Iran. Yet, despite our
expectation, this study did not show any preference of
EBV for upper or middle third of stomach. It is important
to notice that in spite of many confirmatory studies in this
context, there is also no such relation in our nearby coun-
tries, i.e. Kazakhstan [28] and India [18].
EBV in our study did not show any relation with age and
depth of invasion. Some studies indicate that there is ten-
dency of EBV-GC to occur in lower age [19,26,33,38].
However, Koriyama et al [23] revealed that only intestinal
type of EBV-GC shows this age preference, and proposed
that difference in age of exposure to specific cofactors for
each of these types is the probable reason.
One of the interesting findings of the present study is the
fact that 6 out of our 9 EBV-GC cases which were selected
randomly, were born during the period between 1928 and
1930. Although we could not perform any analysis in
regard of the low number of positive cases, this finding
seems important since an epidemiological study sug-
gested that EBV infection at early childhood may be
related to the development of EBV-GC in adulthood [71].
Although we have no evidence, some hypothesis could be
considered. For example, specific conditions or events,
leading to EBV infection in early childhood or resulting to
exposure to some specific co-risk factors which might
have existed around the late 1920s. Therefore, we propose
a case control study focusing on gastric carcinoma in
patients born around the late 1920s to compare the prev-
alence of EBV in these patients with the others.
Genotyping of the virus revealed that type 1 is the exclu-
sive type in all of our EBV-GC. The predominance of type
1 is in agreement with other studies [18,45,58,40]. Type 2
is mostly seen in Africa [40] and there is a belief that it is
weaker than type 2 and is mostly seen in immunodefi-
cient patients [40,72]. The prototype F at BamHI-F was the
most common type in this study. This type has a world-
wide distribution except in southern China which "f" var-
iant is prevalent and causes nasopharyngeal carcinoma
[43,45]. Our finding is the same as similar studies in gas-
tric cancers in India [18], Japan [73], and Chile [58].
BamHI-W1/I1 region polymorphism analysis shows that
90% of our cases were type "i". Previous studies revealed
that type I is the most prevalent in Asia [45,54] and type
"i" is the most in western countries [46]. This pattern of
distribution had been also seen in similar studies on EBV-
GC [18,45,73]. However, our finding seems to be similar
to western countries like Corvalan findings in Colombia
and Chile [58]. XhoI+ was the most prevalent type at XhoI
restriction site in exon one of LMP1 gene in the present
study. This finding is also similar to Corvalan finding in
EBV-GC in Colombia and Chil [58] and in contrast to
findings in eastern Asia [44].
The most important finding in this study was the combi-
nation of "i"/XhoI+ in 6 of our cases. Corvalan et al had
shown that this combination is significantly more in EBV-
GC than healthy people [58]. They propose that the exist-
ence of certain gene with transforming capacity in the
vicinity of these sites is the probable explanation of more
tumorigenecity of this variant. This finding is against the
belief that EBV strains are geographically distributed but
not disease restricted [73]. However, we need first to eval-
uate the genotype of EBV in healthy people in Iran before
any conclusion. To our knowledge, the genotype distribu-
tion among healthy population in Iran is not reported in
the literature.
Conclusion
In summary, we could say that our study is the first to
describe the frequency of EBV-GC in Iran and in the Mid-
dle East, highlighting a very low prevalence. The most
important feature of the present study is the fact that we
could use the cases diagnosed as early as 1960. Such a fea-
ture made it possible to examine the effect of birth year.
Interestingly, EBV-GC in the present study was dominated
by the patients born during the period between 1928 and
Result of XhoI polymorphism in southern blot hybridization Figure 4
Result of XhoI polymorphism in southern blot 
hybridization. Each sample was loaded in 2 lanes with and 
without enzyme respectively from left. The first and the sec-
ond specimens are cleaved with enzyme which means they 
are XhoI+. The third one is XhoI-. (+: positive control; +/
enz: positive control with enzyme; -: negative control).Diagnostic Pathology 2007, 2:25 http://www.diagnosticpathology.org/content/2/1/25
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1930. Most of other findings such as diffuse histology,
weak male predominance and genotype of the cases were
similar to studies performed in Latin America.
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